Belskaya A, Kurzina N, Savchenko A, Sukhanov I, Gromova A, Gainetdinov R
Biomedicines. 2024; 12(6).
PMID: 38927477
PMC: 11200708.
DOI: 10.3390/biomedicines12061270.
Riederer P, Horowski R
J Neural Transm (Vienna). 2023; 130(11):1323-1335.
PMID: 37796288
PMC: 10645634.
DOI: 10.1007/s00702-023-02692-9.
Savchenko A, Targa G, Fesenko Z, Leo D, Gainetdinov R, Sukhanov I
Biomolecules. 2023; 13(5).
PMID: 37238676
PMC: 10216310.
DOI: 10.3390/biom13050806.
Bhattacharyya K
Ann Indian Acad Neurol. 2022; 25(1):124-130.
PMID: 35342258
PMC: 8954318.
DOI: 10.4103/aian.aian_474_21.
Fahn S
Mov Disord Clin Pract. 2021; 8(7):993-996.
PMID: 34631934
PMC: 8485602.
DOI: 10.1002/mdc3.13337.
Oleh Hornykiewicz, a giant in the understanding and treatment of Parkinson disease.
Zecca L, Pifl C, Fahn S, Sulzer D, Fariello R
NPJ Parkinsons Dis. 2021; 7(1):1.
PMID: 33397996
PMC: 7782676.
DOI: 10.1038/s41531-020-00149-4.
Presynaptic dopamine deficit in minimally conscious state patients following traumatic brain injury.
Fridman E, Osborne J, Mozley P, Victor J, Schiff N
Brain. 2019; 142(7):1887-1893.
PMID: 31505542
PMC: 6598636.
DOI: 10.1093/brain/awz118.
Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.
Matt S, Gaskill P
J Neuroimmune Pharmacol. 2019; 15(1):114-164.
PMID: 31077015
PMC: 6842680.
DOI: 10.1007/s11481-019-09851-4.
Dopamine in psychiatry: a historical perspective.
Foley P
J Neural Transm (Vienna). 2019; 126(4):473-479.
PMID: 30758785
DOI: 10.1007/s00702-019-01987-0.
Advances in Parkinson's Disease: 200 Years Later.
Del Rey N, Quiroga-Varela A, Garbayo E, Carballo-Carbajal I, Fernandez-Santiago R, Monje M
Front Neuroanat. 2019; 12:113.
PMID: 30618654
PMC: 6306622.
DOI: 10.3389/fnana.2018.00113.
Human tyrosine hydroxylase in Parkinson's disease and in related disorders.
Nagatsu T, Nakashima A, Ichinose H, Kobayashi K
J Neural Transm (Vienna). 2018; 126(4):397-409.
PMID: 29995172
DOI: 10.1007/s00702-018-1903-3.
Dopamine and the Brainstem Locomotor Networks: From Lamprey to Human.
Ryczko D, Dubuc R
Front Neurosci. 2017; 11:295.
PMID: 28603482
PMC: 5445171.
DOI: 10.3389/fnins.2017.00295.
Levodopa in Parkinson's Disease: Current Status and Future Developments.
Tambasco N, Romoli M, Calabresi P
Curr Neuropharmacol. 2017; 16(8):1239-1252.
PMID: 28494719
PMC: 6187751.
DOI: 10.2174/1570159X15666170510143821.
The two-century journey of Parkinson disease research.
Przedborski S
Nat Rev Neurosci. 2017; 18(4):251-259.
PMID: 28303016
DOI: 10.1038/nrn.2017.25.
The Synucleinopathies: Twenty Years On.
Goedert M, Jakes R, Spillantini M
J Parkinsons Dis. 2017; 7(s1):S51-S69.
PMID: 28282814
PMC: 5345650.
DOI: 10.3233/JPD-179005.
L-DOPA.
Hornykiewicz O
J Parkinsons Dis. 2017; 7(s1):S3-S10.
PMID: 28282813
PMC: 5345651.
DOI: 10.3233/JPD-179004.
Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.
Kish S, Boileau I, Callaghan R, Tong J
Eur J Neurosci. 2016; 45(1):58-66.
PMID: 27519465
PMC: 5209286.
DOI: 10.1111/ejn.13363.
Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.
Nagatsu T, Nagatsu I
J Neural Transm (Vienna). 2016; 123(11):1255-1278.
PMID: 27491309
DOI: 10.1007/s00702-016-1596-4.
Regional cerebral metabolic patterns demonstrate the role of anterior forebrain mesocircuit dysfunction in the severely injured brain.
Fridman E, Beattie B, Broft A, Laureys S, Schiff N
Proc Natl Acad Sci U S A. 2014; 111(17):6473-8.
PMID: 24733913
PMC: 4035959.
DOI: 10.1073/pnas.1320969111.
Contributions to the field of neurotransmitters by Japanese scientists, and reflections on my own research.
Otsuka M
Proc Jpn Acad Ser B Phys Biol Sci. 2013; 83(2):47-64.
PMID: 24019584
PMC: 3756739.
DOI: 10.2183/pjab.83.47.
